Ovarian cancer recurrence detection study pulled before starting
NCT ID NCT05991752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see if a blood test called the ROMA score could find ovarian cancer coming back sooner than the usual CA125 test. The goal was to catch recurrences early, which might allow less invasive surgery and improve quality of life. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Could centralized surgery boost ovarian cancer survival?
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New PET tracer aims to spot hidden cancer spread in the abdomen